Senator asks FDA chief for info relating to Genentech

Share this article:

Sen. Herb Kohl (D-WI) has asked commissioner Andrew von Eschenbach for info relating to the FDA's role in a decision by Genentech to limit availability of its cancer drug Avastin to certain drug compounding pharmacies. Kohl said some physicians have charged that Genentech is taking the step to boost sales of its Lucentis, which is much more expensive than Avastin. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.